<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336750</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2014-15 CBCSG019</org_study_id>
    <nct_id>NCT02336750</nct_id>
  </id_info>
  <brief_title>Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis</brief_title>
  <official_title>A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing Dexamethasone, Aprepitant and Mirtazapine With Dexamethasone and Aprepitant in
      Delayed Emesis Control and Appetite Improvement
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase III Trial Comparing Efficacy and Safety of Dexamethasone, Aprepitant and Mirtazapine
      With Dexamethasone and Aprepitant in Delayed Emesis Control and Appetite Improvement
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed emesis control (no vomiting and no rescue treatment during 25-120 hours after initiation of chemotherapy)</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety of treatment group and control group. (number of participants with adverse events)</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess appetite improvement after adding Mirtazapine treatment by using Food Diary.</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess complete response (CR) rate during 0-24 hours after initiation of chemotherapy, to examine differences in acute emesis control after adding Aprepitant treatment.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess complete response (CR) rate during 0-120 hours after initiation of chemotherapy.</measure>
    <time_frame>120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>no rescue antiemetic therapy in 0-24 hours, 0-120 hours and 25-120 hours after initiation of chemotherapy</measure>
    <time_frame>24 hours; 120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first vomiting episode, time to first rescue antiemetic therapy and time to treatment failure (based on first vomiting episode or first rescue antiemetic therapy, whichever occurs first)</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact on patients' daily life activities in both acute and delayed emesis phases after chemotherapy by using the Functional Living Index -Emesis (FLIE).</measure>
    <time_frame>120 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess impact of nausea and vomiting on compliance of patients receiving chemotherapy.</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>125mg D1, 80mg D2-3</description>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Aprepitant Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>15mg D2-4</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Mirtazapine Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who had delayed emesis after receiving AC regimen or regimens including
             cisplatin, and will subsequently accept the same chemotherapy regimens

          2. Karnofsky Performance Status ≥60.

          3. Life expectancy of more than 3 months.

          4. Hemoglobin ≥ 90 g/L (No blood transfusion within 14 days), Absolute Neutrophil Count ≥
             1.5×10^9/L, Platelet Count ≥ 75×10^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤
             3.0×ULN (without liver metastases), ALT and AST ≤ 5.0×ULN (with liver metastases),
             Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance＞60ml/min

          5. Be able to read, understand and complete the questionnaire and diary, including FLIE
             and Food Diary. Note: Must be able to understand written Chinese.

          6. Be able to understand the study procedures and sign informed consent.

          7. Meet one of the followings about contraception:

        For fertile women：

          1. Urine pregnancy test in screening should be negative. If urine pregnancy test is
             positive, the patient could be enrolled only when serum pregnancy test is negative.

          2. They should agree to abstinence or use double barrier methods of contraception during
             the research, within at least 14 days before enrolling and one month after the last
             dose of study medicine.

          3. If taking oral contraceptives, the patient should agree to add a barrier method of
             contraception during the research, within at least 14 days before enrolling and one
             month after the last dose of study medicine.

        Unfertility is defined as anyone of the followings:

          1. Natural menopausal (natural menopausal ≥6 months and the serum FSH in the
             Postmenopausal range, or natural menopausal ≥12 months and age ＞45)

          2. Bilateral tubal ligation

          3. 6 weeks after the bilateral oophorectomy (with or without hysterectomy )

        Exclusion Criteria:

          1. Treatment with any other study medicine within 4 weeks before enrollment and with
             unrecovered toxicities.

          2. Women of reproductive age (including gestation period, lactation, a desire of
             pregnancy, oral contraceptives only)

          3. Severe visceral disease: such as history of myocardial infarction or serious epilepsy
             needing medicine.

          4. Mental disabilities or emotional or mental disorders.

          5. Another malignancy within 5 years (except for cured basal cell carcinoma of the skin
             and cervical carcinoma).

          6. Uncontrolled disease, such as active infections (pneumonia), diabetic ketoacidosis,
             gastrointestinal obstruction. And other cases which would cause bias or make patients
             exposed to unnecessary risks.

          7. Receiving any dose of systemic glucocorticoid treatment, but local or inhaled
             corticosteroids is allowed.

          8. Benzodiazepines or opioids treatment within 48 hours before the first day of the
             study, except for a single daily taking of triazolam, temazepam or midazolam.

             a)Benzodiazepines or opioids given 48 hours or longer before the first day of the
             study are allowed and patients can continue the medication.

          9. Having vomiting, retching or nausea within 24 hours before cisplatin treatment on the
             first day of the study.

         10. Patient will receive abdominal or pelvic radiation between a week before and 6 days
             after the initiation of the study.

         11. Prior aprepitant treatment or hypersensitivity history to any components of the study
             drug.

         12. Cannot swallow capsules.

         13. Not eligible for the study based on the investigators.

         14. Patients receiving strong inducers of CYP3A4, such as carbamazepine, dipheninum,
             phenobarbitone, etc..
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>5006</phone_ext>
    <email>huxicun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Cao, MD</last_name>
    <phone>64175590</phone>
    <phone_ext>5009</phone_ext>
    <email>caojun1115lemon@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, MD,PhD</last_name>
      <phone>64175590</phone>
      <phone_ext>5006</phone_ext>
      <email>huxicun@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Cao, MD</last_name>
      <phone>64175590</phone>
      <phone_ext>5009</phone_ext>
      <email>caojun1115lemon@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Vice Director of department of medical oncology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

